HTG2014-Section-Header-publications

Publications

Explore HTG publications
with our new search tool. Launch Now

Categories

Reset Categories

Filter by Topics

AACR2023 ADCC Gene Alteration adolescents ALK Angiogenesis Apoptosis Autocrine Signaling B-accute lyphoblastic seukemia B-ALL Biology of neoplasia Biomarkers Bladder Cancer Blastic plasmacytoid dandritic cell neoplasm BPDCN Blood bone Brain Breast Cancer CAR T cell therapy Cardiovascular Disease CDKN2A mutation Cell Free Plasma Cells Chemokines Circulating miRNAs clinical trial Colorectal cancer Comparison study Core Needle Biopsy COVID-19 Custom mRNA Cytokines Developmental Immunotherapy Developmental Therapeutics Diabetes Differential Expression Differential Gene Expression Analysis DLBCL Drug Response Drug sensitivity Efficacy EHE cancer EMT Epstein-Barr ERBB3 Esophageal Cancer estrogen and progesteron receptors Exosomes extracellular miRNAs Extracellular Vesicles Feasibility FFPE FGF Ligand Trap FGFR Follicular lymphoma Gene Expression Gene Expression Profiling Gene Fusions Gene Signature Analysis Genetic Polymorphism Genitourinary cancer Glioblastoma Tumors Head and Neck Cancer Heart HER-2 HER2- HLA-E Homing HPV HR+ HTG EdgeSeq ALKPlus Assay EU HTG EdgeSeq DLBCL Cell of Origin Assay HTG EdgeSeq DLBCL Cell of Origin Assay EU HTG EdgeSeq EGFR KRAS and BRAF Mutation Assay HTG EdgeSeq Immune Response Panel HTG EdgeSeq Immuno-Oncology Assay HTG EdgeSeq Immuno-Oncology Panel HTG EdgeSeq Lung Fusion Assay HTG EdgeSeq miRNA Whole Transcriptome Assay HTG EdgeSeq miRNA Whole Transcriptome Panel HTG EdgeSeq Oncology Biomarker Panel HTG EdgeSeq PATH Assay HTG EdgeSeq Precision Immuno-Oncology Panel HTG EdgeSeq System Immune Cells Immune Checkpoint Inhibitors Immune Response Immune System Immuno-Oncology Immunotherapy Integrins IOA- 244 IRP Kidney LAG3+ Liposarcoma Liquid Biopsy liver Liver liver tissue Lung lungs Lupus Lymphocytes lymphoma Lymphoma melanoma Melanoma Mesothelioma Microenvironment miRNA miRNA WTA Molecular Characterization Mouse mRNA custom mTOR signaling Multiple Myeloma MYC Natural Killer Cells Neoantigens Novel Therapeutic Targets OBP Oral Cancer Oral cancer oral squamous cell carcinoma OSCC Osteoarthritis palbociclib PALLET PALOMA PALOMA-2 PanB Pancreas Pathway Analysis Patient Stratification PAXgene PBMCs PCA Cell Lines PD-L1 PDX model PENELOPE-B PFAS PI3K inhibitors PIK3CA mutation PIP Plasma Platform Comparison Programmed cell death protein 1 Prostate Prostate Cancer qNPA qPCR Rbsig Renal Cell Carcinoma Reproductive Reveal Rheumatoid Arthritis safety Sarcoma Serum Signaling Inhibitors Signaling Pathways Signature Validation Signatures Sinonasal Carcinoma Squamous cell carcinoma STAT6 pathway Sub-typing Testicular cancer Therapeutic Response TMB Toxicity TP53 mutation Transplantation Treatment Outcome Treatment Stratification Triple Negative Breast CancerTNBC Tumor Biology Tumor Immunobiology Tumor infiltrating lymphocytes Tumor Microenvironment tumor microenvironment Urine Urothelial carcinoma VEGFR Xenograft Tissue
Reset Filter Reset All

2020

Neratinib plus Cetuximab in Quadruple WT (KRAS, NRAS, BRAF, PIK3ca) Metastatic Colorectal Cancer Resistant to Cetuximab or Panitumumab: NSABP FC-7, A Phase Ib Study

Jacobs, S. A., et al. Neratinib plus Cetuximab in Quadruple WT (KRAS, NRAS, BRAF, PIK3ca) Metastatic Colorectal Cancer Resistant to Cetuximab or Panitumumab: NSABP FC-7, A Phase Ib Study. Clinical Cancer Research 2020 NOV 17 DOI: 10.1158/1078-0432.CCR-20-1831

View External Link

Variation in Genetic Polymorphisms and Gene Expression of HLA-E to Predict Outcomes in Metastatic Colorectal Cancer (mCRC) Patients (pts) Treated with First-line FOLFIRI/Cetuximab: Data from the Phase III FIRE-3 Trial.

Naseem, M., et al. Variation in Genetic Polymorphisms and Gene Expression of HLA-E to Predict Outcomes in Metastatic Colorectal Cancer (mCRC) Patients (pts) Treated with First-line FOLFIRI/Cetuximab: Data from the Phase III FIRE-3 Trial. Poster session presented at Gastrointestinal Cancers Symposium. 2020 Jan 25. San Francisco, CA. J Clin Oncol 38, 2020 (suppl 4; abstr 245)

View External Link

CCR5 Δ32 Mutation and Gene Expression to Predict Outcome in Patients (pts) with Metastatic Colorectal Cancer (mCRC): Data From FIRE-3 and MAVERICC Phase III Trials.

Lenz, A., et al. CCR5 Δ32 Mutation and Gene Expression to Predict Outcome in Patients (pts) with Metastatic Colorectal Cancer (mCRC): Data From FIRE-3 and MAVERICC Phase III Trials.  Poster session presented at 2020 Gastrointestinal Cancers Symposium. 2020 Jan 25. San Francisco, CA. J Clin Oncol 38, 2020 (suppl 4; abstr 170)

View External Link

Genetic variants in R-Spondin/RNF43 complex and gene expression levels to predict efficacy of cetuximab (cet) in patients (pts) with metastatic colorectal cancer (mCRC): Data from the FIRE-3 phase III trial.

Battaglin, F., et al. Genetic variants in R-Spondin/RNF43 complex and gene expression levels to predict efficacy of cetuximab (cet) in patients (pts) with metastatic colorectal cancer (mCRC): Data from the FIRE-3 phase III trial. Poster session  Clin Oncol 38, 2020 (suppl 4; abstr 190) presented at 2020 Gastrointestinal Cancers Symposium; 2020 Jan 25; San Francisco, CA.

View External Link

2019

Gene expression and genetic variants in Parkinson's disease (PD) genes to predict outcome in metastatic colorectal cancer (mCRC): Data from FIRE-3 phase III trial.

Battaglin, F., et al. Gene expression and genetic variants in Parkinson's disease (PD) genes to predict outcome in metastatic colorectal cancer (mCRC): Data from FIRE-3 phase III trial. Paper presented at: American Society of Clinical Oncology (ASCO) Annual Meeting; June 3, 2019, Chicago, IL

View External Link

Genetic variants in the lipopolysaccharide (LPS) receptor complex and TLR4 expression levels to predict the efficacy of cetuximab (cet) in patients (pts) with metastatic colorectal cancer (mCRC): Data from the FIRE-3 phase III trial.

Battaglin, F., et al. Genetic variants in the lipopolysaccharide (LPS) receptor complex and TLR4 expression levels to predict the efficacy of cetuximab (cet) in patients (pts) with metastatic colorectal cancer (mCRC): Data from the FIRE-3 phase III trial.  American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium; January 19, 2019, San Francisco, CA.

View External Link

2018

A biomarker study to validate predictors for clinical outcome of cetuximab based chemotherapy in first-line metastatic colorectal cancer (mCRC)patients

Sunakawa, Y. et al. A biomarker study to validate predictors for clinical outcome of cetuximab based chemotherapy in first-line metastatic colorectal cancer (mCRC)patients. Abstract presented at: 2018 Congress European Society for Medical Oncology (ESMO); 2018 Oct 21; Munich, Germany. Annals of Oncology (2018) 29 (suppl_8): viii150-viii204. 10.1093/annonc/mdy281.

View External Link

2017

2016

Association of gene signature to identify molecular subtypes with clinical outcomes of 1st-line cetuximab (cet) treatment for metastatic colorectal cancer (mCRC)

Sunakawa, Y., et al. Association of gene signature to identify molecular subtypes with clinical outcomes of 1st-line cetuximab (cet) treatment for metastatic colorectal cancer (mCRC). J Clin Oncol. 2016;34(Suppl):abstr 3592.

View External Link

Evaluation and selection of a non-PCR based technology for improved gene expression profiling from clinical formalin-fixed, paraffin-embedded samples

Qi Z., et al. Evaluation and selection of a non-PCR based technology for improved gene expression profiling from clinical formalin-fixed, paraffin-embedded samples. Bioanalysis. 2016 Oct 7.

PMID: 27712086

Download pdf 1.0MB
View External Link

Page last updated May 22, 2023